- Home
- EUDA vs CLLS Comparison
EUDA vs CLLS Comparison
Compare EUDA & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EUDA
- CLLS
- Stock Information
- Founded
- EUDA 2021
- CLLS 1999
- Country
- EUDA Singapore
- CLLS France
- Employees
- EUDA N/A
- CLLS N/A
- Industry
- EUDA Blank Checks
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- EUDA Finance
- CLLS Health Care
- Exchange
- EUDA Nasdaq
- CLLS Nasdaq
- Market Cap
- EUDA 146.0M
- CLLS 143.4M
- IPO Year
- EUDA N/A
- CLLS 2007
- Fundamental
- Price
- EUDA $3.21
- CLLS $1.59
- Analyst Decision
- EUDA
- CLLS Buy
- Analyst Count
- EUDA 0
- CLLS 1
- Target Price
- EUDA N/A
- CLLS $4.00
- AVG Volume (30 Days)
- EUDA 98.7K
- CLLS 48.2K
- Earning Date
- EUDA 01-01-0001
- CLLS 08-05-2025
- Dividend Yield
- EUDA N/A
- CLLS N/A
- EPS Growth
- EUDA N/A
- CLLS N/A
- EPS
- EUDA N/A
- CLLS N/A
- Revenue
- EUDA $4,011,005.00
- CLLS $54,747,000.00
- Revenue This Year
- EUDA $212.19
- CLLS $48.52
- Revenue Next Year
- EUDA $254.35
- CLLS $5.17
- P/E Ratio
- EUDA N/A
- CLLS N/A
- Revenue Growth
- EUDA 8.22
- CLLS 351.26
- 52 Week Low
- EUDA $2.92
- CLLS $1.10
- 52 Week High
- EUDA $6.30
- CLLS $2.43
- Technical
- Relative Strength Index (RSI)
- EUDA 37.78
- CLLS 56.98
- Support Level
- EUDA $3.15
- CLLS $1.56
- Resistance Level
- EUDA $3.60
- CLLS $1.49
- Average True Range (ATR)
- EUDA 0.14
- CLLS 0.09
- MACD
- EUDA -0.04
- CLLS 0.01
- Stochastic Oscillator
- EUDA 0.46
- CLLS 80.00
About EUDA EUDA Health Holdings Limited
EUDA Health Holdings Ltd is a non-invasive healthcare company across Southeast Asia and China. The Company has two reportable segments: property management services and holistic wellness consumer products and services. Key revenue is generated from property management services that include common area property management services that contain cleaning, landscaping, public facilities maintenance and other traditional services and also include security property management services provided to all tenants and property owners.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.